Patients with HCV may deliberately skip early treatment doses when feeling well
Medication nonadherence during the first 24 weeks of treatment for chronic hepatitis C was often deliberate and attributed to feeling well, as opposed to forgetfulness or other factors, in a recent study.
Researchers evaluated adherence to treatment in a cohort of 401 patients with chronic HCV genotype 1. All participants had been enrolled in the Virahep-C study and received therapy with pegylated interferon (PEG) and ribavirin (RBV) for 24 weeks, with responders receiving an additional 24 weeks (n=242). Adherence was measured using the Medication Event Monitoring System, which recorded when the medication container was opened via a computer chip in the cap.
Full Story »
- Newly Diagnosed
- All FDA Approved Drugs To Treat Hepatitis C
- 2017-HCV Genotypes/Treatment
- Epclusa® (Sofosbuvir/Velpatasvir)
- Harvoni® (Ledipasvir/Sofosbuvir)
- VIEKIRA XR/VIEKIRA Pak
- Not FDA Approved - Sofosbuvir/Velpatasvir/Voxilaprevir
- Not FDA Approved - Glecaprevir/Pibrentasvir (G/P)
- NOT FDA Approved - MK3 (MK-3682/grazoprevir/ruzasvir1)
- Cure - Achieving sustained virologic response (SVR) in hepatitis C
- FibroScan® Understanding The Results
- Is There A Natural Way To Improve Liver Fibrosis?
- Staging Cirrhosis